Avicidin

Avicidin

An investigational radioimmunotherapeutic agent for treating advanced therapeutically refractive cancers of the colon, ovarian and prostate, which delivers high-dose RT to metastatic tumours, while minimising exposure of normal tissues, especially bone marrow. Avicidin was discontinued in phase-II trials due to a high incidence of unacceptable diarrhea, which was atributed to cross-reactivity of the Avicidin anti-Epcam antibody with the intestine.